|
Market Closed -
Nasdaq
16:00:00 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 1.630 USD | -5.78% |
|
-7.91% | -76.13% |
Company Valuation: TransCode Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 31.92 | 8.457 | 4.136 | 2.346 | 6.263 |
| Change | - | -73.5% | -51.1% | -43.27% | 166.92% |
| Enterprise Value (EV) 1 | 11.08 | 3.479 | 1.819 | -3.426 | -11.55 |
| Change | - | -68.61% | -47.73% | -288.39% | -237.11% |
| P/E | - | - | - | -0.07x | -0.13x |
| PBR | - | - | - | -1.72x | 0.61x |
| PEG | - | - | - | - | 0x |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | -1.8x | -0.19x | -0.09x | 0.22x | 0.6x |
| EV / FCF | -3x | -0.35x | -0.16x | 0.45x | 0.85x |
| FCF Yield | -33.4% | -286% | -616% | 220% | 117% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | - | - | - | -1,320 | -52.59 |
| Distribution rate | - | - | - | - | - |
| Net sales | - | - | - | - | - |
| EBITDA | -6.109 | -18.57 | -19.3 | -15.57 | -19.12 |
| EBIT 1 | -6.151 | -18.67 | -19.42 | -15.66 | -19.19 |
| Net income 1 | -6.843 | -17.56 | -18.55 | -16.75 | -34.66 |
| Net Debt 1 | -20.84 | -4.978 | -2.317 | -5.773 | -17.81 |
| Reference price 2 | 1,877,587.226 | 497,486.694 | 6,091.003 | 94.360 | 6.830 |
| Nbr of stocks (in thousands) | 0.02 | 0.02 | 0.68 | 24.9 | 917 |
| Announcement Date | 3/31/22 | 3/31/23 | 4/1/24 | 4/15/25 | 4/15/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 27.6M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.85x | 0.86% | 54.62B | |
| 34.93x | 3.32x | 14.34x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -64.56x | 13.05x | -73.23x | -.--% | 24.7B | |
| Average | 18.13x | 28.02x | 6.57x | 0.34% | 39.44B | |
| Weighted average by Cap. | 22.09x | 26.34x | 10.94x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RNAZ Stock
- Valuation TransCode Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
